ERK1 and ERK2, which are key protein kinases in Ras-Raf-MEK-ERK-MAPK signaling, are associated with apoptosis, cell proliferation, and immune response in cancer, and ERK inhibitors have been used in early clinical trials to treat various advanced/metastatic solid tumors [34]. Here, MAP2K7 is linked to cancer.